RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @EricTopol: And another adenovirus vector vaccine Phase 2 trial (CanSIno) in China, published @TheLancet today, also found neutralizing…
لقاح CanSino: https://t.co/lPAGAx45tU
RT @pmarsupia: 🔴 Más buenas noticias! The Lancet también ha publicado los resultados de la Fase II de la farmacéutica china CanSino (sí,…
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
@paulrikmans @RiaDickmann @r3ev @sandravogelaar Ik ben geloof ik zojuist geblokt door Sandra. Kan ze dan mijn tweets nog wel zien? Als niet, wel jammer want hier is er één, heet van de naald: https://t.co/Y7T1mhaRA2
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @mayogastro: Excelente. Esta vacuna parece efectiva con pocos efectos 2rios. Immunogenicity and safety of a recombinant adenovirus type-…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @mayogastro: Excelente. Esta vacuna parece efectiva con pocos efectos 2rios. Immunogenicity and safety of a recombinant adenovirus type-…
Excelente. Esta vacuna parece efectiva con pocos efectos 2rios. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial h
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
So we got China, Russia and England all with good trails this week. That's great news. We might even find different vaccines. That's great too, it decreases the chance of someone monetizing it
@danieloso Está reñida la competencia https://t.co/Wes2zq4DmJ
RT @JuanUrregoR: Aquí está el otro fase II del día, en este caso, el conducido en China. Todo hay que decirlo, fueron bastante honestos res…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
pls let china sort this vaccine first am begging xxxx
RT @virolvlog: أخبار جيدة: أظهر دراستان نشرتا اليوم أن لقاح جامعة أكسفورد ولقاح شركة كانسينو الصينية (كلاهما يعتمد على تقنية ناقل أدينو) أث…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
Let’s goooooooo!!!
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
@OneWayTicketSA @CNBCnow It was published today in @TheLancet , this is why news channels are covering the story today. If you really wanted to know, you could probably have found that out yourself. Just in case, here's the link. https://t.co/j7eIv8OryF
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @pmarsupia: 🔴 Más buenas noticias! The Lancet también ha publicado los resultados de la Fase II de la farmacéutica china CanSino (sí,…
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial -The Lancet https://t.co/6BtmkHxD9g
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @pmarsupia: 🔴 Más buenas noticias! The Lancet también ha publicado los resultados de la Fase II de la farmacéutica china CanSino (sí,…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @AB_Algaissi: أخبار جميلة اليوم عن اللقاحات: نشر نتائج المرحلة السريرية ١ للقاح جامعة أكسفورد والنتائج مشجعة جداً. https://t.co/qzBJVYI…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @pmarsupia: 🔴 Más buenas noticias! The Lancet también ha publicado los resultados de la Fase II de la farmacéutica china CanSino (sí,…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @iaiestaran: Vacuna china en fase 2 resulta segura y produce respuesta inmune en la epidemia de coronavirus #COVID19, según estudio publ…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: Phase 3 trials are needed to confirm whether the vaccine candidate effectively protects against SARS-CoV-2 infection https:/…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
Immunogenicity and safety of CanSino Biologics recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/OuS2Qd1FHF
RT @SIDPharm: Check out the phase 1/2 vaccine trials published in @TheLancet today #COVID19 #IDTwitter ChAdOx1 https://t.co/HhLxI684bs Ad…
RT @SIDPharm: Check out the phase 1/2 vaccine trials published in @TheLancet today #COVID19 #IDTwitter ChAdOx1 https://t.co/HhLxI684bs Ad…
RT @carrie_byington: Data from China. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy a…
RT @SIDPharm: Check out the phase 1/2 vaccine trials published in @TheLancet today #COVID19 #IDTwitter ChAdOx1 https://t.co/HhLxI684bs Ad…
Check out the phase 1/2 vaccine trials published in @TheLancet today #COVID19 #IDTwitter ChAdOx1 https://t.co/HhLxI684bs Ad5-vectored https://t.co/Lu0DLHuKt9 Comment https://t.co/qYQH9aKbGD https://t.co/AtxVaOITre
Data from China. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/0VbQP6N9Lm
La mejor opción de vacuna para COVID19 es la de virus atenuados, producida por Oxford y AztraZeneca. #Apunten https://t.co/8QDYTFWsXw
@weirdmedicine Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/RpjZr0XRr3
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet https://t.co/MdJD4PGCgp
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/nOspu7MLVi
Oxford Astra Zeneca adenovirus vector vaccine Result of single blind RCT combined phase1/2 trial. https://t.co/iDVLBarkJx
➡️Vacuna china: adenovirus como vector. Phase 2 trial (CanSiNo) https://t.co/Mh0zZpTGK8 https://t.co/ID0Pmuj6wh
Links. Here is the paper from the Oxford group https://t.co/K67Ni6CCyW And here is the one where the corresponding authors are from Wuhan, Beijing, and Nanjing. https://t.co/vROisGhqRG
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/eVPftUNv7d
That's one small step for a man, one giant leap for mankind https://t.co/vjc14c27yY
Inmunogenicidad y seguridad de una vacuna COVID-19 vectorizada con adenovirus recombinante tipo 5 en adultos sanos de 18 años de edad o mayores: un ensayo aleatorizado, doble ciego, controlado con placebo, fase 2 https://t.co/XHI1LyvmDd
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/f9noLA68mh